Advertisement

Comparison of Usefulness of Cardiac Resynchronization Therapy in Patients With Type 1 Myotonic Dystrophy With Versus Without Left Bundle Branch Block

Published:September 09, 2019DOI:https://doi.org/10.1016/j.amjcard.2019.08.039
      Patients with type 1 myotonic dystrophy show reduced left ventricular systolic function in the presence of left bundle branch block due to electromechanical dys-synchrony. Our prospective study tracked a cohort of 64 type 1 myotonic dystrophy patients that demonstrated a high burden of atrial and ventricular arrhythmias and conduction delays. Of these patients, 12 (19%) patients had left bundle branch block, which was associated with reduced left ventricular systolic function. Eight of these patients received cardiac resynchronization therapy devices resulting in reduction of median QRS complex duration from 173 to 166 ms (p = 0.04), and improvement in median left ventricular ejection fraction from 37% to 46% (p = 0.007). In conclusion, cardiac resynchronization therapy device therapy is both feasible and effective in treating advanced cardiac disease in this vulnerable group of patients by improving left ventricular function.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kirk JA
        • Kass DA
        Cellular and molecular aspects of dyssynchrony and resynchronization.
        Heart Fail Clin. 2017; 13: 29-41
        • Auffret V
        • Martins RP
        • Daubert C
        • Leclercq C
        • Le Breton H
        • Mabo P
        • Donal E
        Idiopathic/iatrogenic left bundle branch block-induced reversible left ventricle dysfunction: JACC state-of-the-art review.
        J Am Coll Cardiol. 2018; 72: 3177-3188
        • Bhakta D
        • Shen C
        • Kron J
        • Epstein AE
        • Pascuzzi RM
        • Groh WJ
        Pacemaker and implantable cardioverter-defibrillator use in a US myotonic dystrophy type 1 population.
        J Cardiovasc Electrophysiol. 2011; 22: 1369-1375
        • Nguyen HH
        • Wolfe 3rd, JT
        • Holmes Jr., DR
        • Edwards WD
        Pathology of the cardiac conduction system in myotonic dystrophy: a study of 12 cases.
        J Am Coll Cardiol. 1988; 11: 662-671
        • Wahbi K
        • Babuty D
        • Probst V
        • Wissocque L
        • Labombarda F
        • Porcher R
        • Becane HM
        • Lazarus A
        • Behin A
        • Laforet P
        • Stojkovic T
        • Clementy N
        • Dussauge AP
        • Gourraud JB
        • Pereon Y
        • Lacour A
        • Chapon F
        • Milliez P
        • Klug D
        • Eymard B
        • Duboc D
        Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1.
        Eur Heart J. 2017; 38: 751-758
        • Wahbi K
        • Meune C
        • Porcher R
        • Becane HM
        • Lazarus A
        • Laforet P
        • Stojkovic T
        • Behin A
        • Radvanyi-Hoffmann H
        • Eymard B
        • Duboc D
        Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease.
        J Am Med Assoc. 2012; 307: 1292-1301
        • Groh WJ
        • Groh MR
        • Saha C
        • Kincaid JC
        • Simmons Z
        • Ciafaloni E
        • Pourmand R
        • Otten RF
        • Bhakta D
        • Nair GV
        • Marashdeh MM
        • Zipes DP
        • Pascuzzi RM
        Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1.
        N Engl J Med. 2008; 358: 2688-2697
        • Nikhanj A
        • Sivakumaran S
        • Miskew-Nichols B
        • Siddiqi ZA
        • Oudit GY
        Ventricular tachycardia in patients with type 1 myotonic dystrophy: a case series.
        Eur Hear J Case Rep. 2019; 3: 1-5
        • Arbustini E
        • Di Toro A
        • Giuliani L
        • Favalli V
        • Narula N
        • Grasso M
        Cardiac phenotypes in hereditary muscle disorders.
        J Am Coll Cardiol. 2018; 72: 2485-2506
        • Tanawuttiwat T
        • Wagner KR
        • Tomaselli G
        • Nazarian S
        Left ventricular dysfunction and conduction disturbances in patients with myotonic muscular dystrophy type i and ii.
        JAMA Cardiol. 2017; 2: 225-228
        • Normand C
        • Linde C
        • Singh J
        • Dickstein K
        Indications for Cardiac resynchronization therapy: a comparison of the major international guidelines.
        JACC Heart Fail. 2018; 6: 308-316
        • Tang AS
        • Wells GA
        • Talajic M
        • Arnold MO
        • Sheldon R
        • Connolly S
        • Hohnloser SH
        • Nichol G
        • Birnie DH
        • Sapp JL
        • Yee R
        • Healey JS
        Rouleau JL and resynchronization-defibrillation for ambulatory heart failure trial I. Cardiac-resynchronization therapy for mild-to-moderate heart failure.
        N Engl J Med. 2010; 363: 2385-2395
        • Epstein AE
        • DiMarco JP
        • Ellenbogen KA
        • Estes NA
        • 3rd Freedman RA
        • Gettes LS
        • Gillinov AM
        • Gregoratos G
        • Hammill SC
        • Hayes DL
        • Hlatky MA
        • Newby LK
        • Page RL
        • Schoenfeld MH
        • Silka MJ
        • Stevenson LW
        • Sweeney MO
        • American College of Cardiology F
        • American Heart Association Task Force on Practice G
        • Heart Rhythm S
        2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
        Circulation. 2013; 127: e283-e352
        • McNally EM
        • Sparano D
        Mechanisms and management of the heart in myotonic dystrophy.
        Heart. 2011; 97: 1094-1100
        • Appert L
        • Menet A
        • Altes A
        • Ennezat PV
        • Bardet-Bouchery H
        • Binda C
        • Guyomar Y
        • Delelis F
        • Castel AL
        • Le Goffic C
        • Guerbaai RA
        • Graux P
        • Tribouilloy C
        • Marechaux S
        Clinical significance of electromechanical dyssynchrony and QRS narrowing in patients with heart failure receiving cardiac resynchronization therapy.
        Can J Cardiol. 2019; 35: 27-34
        • Groh WJ
        • Bhakta D
        Arrhythmia management in myotonic dystrophy type 1.
        J Am Med Assoc. 2012; 308: 337-338
        • Lazarus A
        • Varin J
        • Babuty D
        • Anselme F
        • Coste J
        • Duboc D
        Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study.
        J Am Coll Cardiol. 2002; 40: 1645-1652
        • Gagnon C
        • Chouinard MC
        • Laberge L
        • Veillette S
        • Begin P
        • Breton R
        • Jean S
        • Brisson D
        • Gaudet D
        • Mathieu J
        • Panel DMIE
        Health supervision and anticipatory guidance in adult myotonic dystrophy type 1.
        Neuromuscul Disord. 2010; 20: 847-851